Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
KaNDy Therapeutics Announces Positive Phase 2b Data in Post-Menopausal Women with its Lead Non-Hormonal Product NT-814 ~Phase 2b dose range finding study showed rapid and highly significant...
-
KaNDy Therapeutics Announces Positive Phase 2b Data in Post-Menopausal Women with its Lead Non-Hormonal Product NT-814 ~Phase 2b dose range finding study showed rapid and highly significant...
-
KaNDy Therapeutics announces the appointment of Andrew Kay as Independent Chairman of the Board Stevenage, UK, 7 January 2018 - KaNDy Therapeutics, a clinical-stage company developing a potential...
-
KaNDy Therapeutics announces the appointment of Andrew Kay as Independent Chairman of the Board Stevenage, UK, 7 January 2018 - KaNDy Therapeutics, a clinical-stage company developing a potential...
-
KaNDy Therapeutics announces initiation of Phase 2b trial of NT-814 for the treatment of troublesome post-menopausal symptoms Stevenage, UK, 11 December 2018 - KaNDy Therapeutics, a clinical-stage...
-
KaNDy Therapeutics announces initiation of Phase 2b trial of NT-814 for the treatment of troublesome post-menopausal symptoms Stevenage, UK, 11 December 2018 - KaNDy Therapeutics, a clinical-stage...